Trevena to present at the 2016 RBC Capital Markets' Global Healthcare Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that David Soergel, M.D., its chief medical officer, will present a company overview and update at the 2016 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 23, 2016 at 2:05 p.m. EST in New York.

To access the live audio webcast of the presentation, please visit the “Investors” section of the Company's website at www.trevenainc.com. Following the conclusion of the presentation, the webcast will be archived for 30 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates – oliceridine (TRV130) to treat moderate to severe acute pain intravenously (Phase 3), TRV027 to treat acute heart failure (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).

View source version on businesswire.com: http://www.businesswire.com/news/home/20160217005436/en/

Trevena, Inc.
Jonathan Violin, Ph.D.
Sr. Director, Investor Relations
610-354-8840 x231
jviolin@trevenainc.com

Source: Trevena, Inc.

Released February 17, 2016